Regional and Intravenous Dexamethasone in The Prophylaxis of Rebound Pain After Supraclavicular Block in Upper Limb Surgeries

NCT07074691 | Completed

• 1 other identifier: 36264MS507/2/24
• Study Type: interventional
• Target: 90
• Locations: 1 country
• Sites: 1

Brief Summary

This study aimed to compare the effect of regional and intravenous Dexamethasone in the prophylaxis of rebound pain after supraclavicular block in upper limb surgeries.

Conditions

Regional; Intravenous; Dexamethasone; Prophylaxis; Rebound Pain; Supraclavicular Block; Upper Limb Surgeries

Outcome Measures

Primary Outcomes (1)

• Time to the first request of analgesia

  Time to the first request of analgesia was recorded from the end of surgery till the first dose of pethidine administrated.

  24 hours postoperatively

Secondary Outcomes (4)

• Degree of pain

  24 hours postoperatively

• Patient Satisfaction

  24 hours postoperatively

• Total Analgesics consumption

  24 hours postoperatively

• Incidence of complications

  24 hours postoperatively

Study Arms (2)

Regional Dexamethasone group

EXPERIMENTAL

Patients were generally anesthetized, then a supraclavicular block is given (0.5% bupivacaine + dexamethasone 8 mg regionally), total volume = 20 mL (18 mL 0.5% bupivacaine + 2 mL dexamethasone).

Drug: Regional Dexamethasone

Intravenous Dexamethasone group

EXPERIMENTAL

Patients were generally anesthetized, and then a supraclavicular block was administered (0.5% bupivacaine), with a total volume of 20 mL (18 mL of 0.5% bupivacaine and 2 mL of normal saline).

Drug: Intravenous Dexamethasone

Interventions

Regional Dexamethasone DRUG

Patients were generally anesthetized, then a supraclavicular block is given (0.5% bupivacaine + dexamethasone 8 mg regionally), total volume = 20 mL (18 mL 0.5% bupivacaine + 2 mL dexamethasone).

Regional Dexamethasone group

Intravenous Dexamethasone DRUG

Patients were generally anesthetized, and then a supraclavicular block was administered (0.5% bupivacaine), with a total volume of 20 mL (18 mL of 0.5% bupivacaine and 2 mL of normal saline).

Intravenous Dexamethasone group

Eligibility Criteria

• Age: 21 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age from 21 to 65 years.
• Both sexes.
• American Society of Anesthesiology (ASA) class I-II.
• Undergoing upper limb surgeries.

You may not qualify if:

• Patient refusal.
• History of allergy to drugs used.
• ASA class more than II ( III-IV-..).
• Uncooperative patient.
• Patients on chronic pain medications.
• Coagulopathy.

Sponsors & Collaborators

• Tanta University: lead

Study Sites (1)

Tanta University

Tanta, El-Gharbia, 31527, Egypt

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Resident of Anesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt.

Study Record Dates

• First Submitted: July 10, 2025
• First Posted: July 20, 2025
• Study Start: March 1, 2023
• Primary Completion: February 1, 2025
• Study Completion: February 1, 2025
• Last Updated: July 20, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: After the end of study for one year.
• Access Criteria: The data will be available upon a reasonable request from the corresponding author.

Locations

EG (1)